Abstract Background Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist of considerable clinical importance in the management of type 2 diabetes mellitus, presents a formidable synthetic challenge owing to its extended peptide sequence, multiple stereochemical defined residues, and the presence of labile functionalities prone to side reactions
We included peer-reviewed randomized controlled trials, meta-analyses, and high-quality narrative or systematic reviews written in English that evaluated the effects of GLP-1 receptor agonists (liraglutide, semaglutide, or related analogues), as well as dual GIP/GLP-1 receptor agonists (such as tirzepatide), exercise training, or their combination on weight loss, body composition, metabolic, or cardiovascular outcomes in adults with obesity or type 2 diabetes
Mechanism : Tirzepatide acts in the role of a dual agonist for both GLP-1 and GIP receptors, promoting better appetite control and metabolic function
Cellular maintenance and repair of the kidney
Weve learned a lot about making this easier, and very little of it is on the drug label: Eat smaller meals and stop when you start to feel full